Temsirolimus

Drugbox
IUPAC_name = (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S, 23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24, 25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy- 3- [(1R)-2- [(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl] - 1-methylethyl] -10,21-dimethoxy-6,8,12,14,20,26-hexameth 3H-pyrido [2,1-c] [1,4] oxaazacyclohentriacontine-1,5,11,28, 29(4H,6H,31H)-pentone 4′- [2,2-bis(hydroxymethyl)propionate]

---

CAS_number = 162635-04-3
ATC_prefix =
ATC_suffix =
PubChem = 6918289
DrugBank =
chemical_formula =
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK = POM
legal_US = Rx-only
legal_status =
routes_of_administration = Intravenous
licence_EU = Torisel
licence_US = Torisel

Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, [ [http://www.fda.gov/bbs/topics/NEWS/2007/NEW01644.html FDA.gov] ] and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.

The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months). [ [http://www.drugs.com/nda/torisel_061006.html Drugs.com] ] The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated.

References